Text Size
S
M
L
Japanese
English
About Us
Corporate Information
What is Premium Quality ?
The 8th Mid-term
Business Plan
Product Information
Products in JAPAN
Products in ASIA
Investor Relations
IR News
Management Vision
Highlights of Financial Results
IR Information Office
Shareholder /
Share Information
IR Calendar
Shared Research
Report
Integrated Report
Risk Information
Disclaimers
IR Inquiry
CSR
Basic Policy
Ecology
Community
Human Rights
About Us
Product Information
Investor Relations
CSR
Japanese
English
COMPANY
About Us
GENERIC
Product Information
IR
Investor Relations
CORPORATE SOCIAL RESPONSIBILITY
CSR
Nichi-Iko Group
Integrated Report
INFORMATION
08/11/2020
PRESS RELEASE
Year Ending March 31, 2021 Results of 1st Quarter Settlement of Accounts Supplementary Material (Apr.1 to Jun.30 2020)
07/30/2020
PRESS RELEASE
Notice on Acquisition of A Company to be Established to Take Over Generic Pharmaceutical Business from Teva Takeda Pharma Ltd.
07/30/2020
PRESS RELEASE
Presentation Materials of Acquisition of Generic Pharmaceutical Business from Teva Takeda Pharma Ltd.
06/22/2020
PRESS RELEASE
Consolidated Financial Results for the Fiscal Year Ended March 31, 2020 (IFRS)
06/08/2020
PRESS RELEASE
The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19)
